- Home
- GLPG vs AMPL Comparison
GLPG vs AMPL Comparison
Compare GLPG & AMPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- AMPL
- Stock Information
- Founded
- GLPG 1999
- AMPL 2012
- Country
- GLPG Belgium
- AMPL United States
- Employees
- GLPG N/A
- AMPL N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- AMPL EDP Services
- Sector
- GLPG Health Care
- AMPL Technology
- Exchange
- GLPG Nasdaq
- AMPL Nasdaq
- Market Cap
- GLPG 2.1B
- AMPL 1.7B
- IPO Year
- GLPG 2005
- AMPL 2021
- Fundamental
- Price
- GLPG $31.88
- AMPL $10.87
- Analyst Decision
- GLPG Sell
- AMPL Buy
- Analyst Count
- GLPG 4
- AMPL 10
- Target Price
- GLPG $25.33
- AMPL $13.70
- AVG Volume (30 Days)
- GLPG 184.7K
- AMPL 1.7M
- Earning Date
- GLPG 10-29-2025
- AMPL 11-06-2025
- Dividend Yield
- GLPG N/A
- AMPL N/A
- EPS Growth
- GLPG N/A
- AMPL N/A
- EPS
- GLPG N/A
- AMPL N/A
- Revenue
- GLPG $323,674,692.00
- AMPL $316,571,000.00
- Revenue This Year
- GLPG N/A
- AMPL $15.04
- Revenue Next Year
- GLPG N/A
- AMPL $12.65
- P/E Ratio
- GLPG N/A
- AMPL N/A
- Revenue Growth
- GLPG 5.43
- AMPL 9.93
- 52 Week Low
- GLPG $22.36
- AMPL $7.55
- 52 Week High
- GLPG $33.86
- AMPL $14.88
- Technical
- Relative Strength Index (RSI)
- GLPG 48.29
- AMPL 42.89
- Support Level
- GLPG $30.88
- AMPL $10.97
- Resistance Level
- GLPG $33.63
- AMPL $11.59
- Average True Range (ATR)
- GLPG 0.67
- AMPL 0.45
- MACD
- GLPG -0.05
- AMPL 0.02
- Stochastic Oscillator
- GLPG 36.36
- AMPL 15.29
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About AMPL Amplitude Inc.
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue primarily through selling subscriptions to the platform. The company derives a majority of its revenue from the United States.